1Giorgio B,Lucia M,Flora M,et al.Prevalence of and risk factors for nonalcoholic fatty liver disease:the dionysos nutrition and liver study.Hepatology,2005,42:44 被引量：1
2Bedogni G,Bellentani S.Fatty liver:how frequent is it and why? Ann Hepato1,2004,3:63 被引量：1
3Neuschwander_Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202 被引量：1
4Day CP.Steatohepatitis:a tale of two "hits"? Gastroenterology,1998,114:842 被引量：1
5Anthony J G Hanley,Ken Williams,Andreas Festa,Lynne E Wagenknecht,et al.Liver Markers and Development of the Metabolic Syndrome:The Insulin Resistance Atherosclerosis Study.Diabetes,2005,54,3140 被引量：1
7Marcos E Alfie,William R Treem.Nonalcoholic Fatty Liver Disease.Pediatric Annals.2006.35:290-8. 被引量：1
8Marchesini G,Natale S,Manini R,et al.Review article:the treatment of fatty liver disease associated with the metabolic syndrome.Alimentary Pharmacology & Therapeutics,2005,22:37 被引量：1
9Iannello S,Camuto M,Cavaleri A,et al.Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.Metabolism,2004,53:159 被引量：1
10Edward D,Marc G,Elaine K,et al.Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.Hepatology,2005,41:753 被引量：1
二级参考文献25
1Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358: 893-894. 被引量：1
2Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med, 2000, 6: 998-1003. 被引量：1
3Kanauchi M. A new index of insulin sensitivity obtained from the oral glucose tolerance test applicable to advanced type 2 diabetes. Diabetes Care, 2002, 25: 1891-1892. 被引量：1
4Youssef W, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis, 2002, 13: 17-30. 被引量：1
5Glueck C J, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic overian syndrome. Metabolism, 2003,52: 908-915. 被引量：1
6Maciel GA, Soares Junior JM, Alves da Motta EL, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril, 2004,81: 355-360. 被引量：1
7Mayerson AB, Hondal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes, 2002,51:797-802. 被引量：1
8Voberti G, kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial(ADOPT). An international muticenter study of the comparative efficacy of rosiglitazone, glyburide and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002,25: 1737-1743. 被引量：1
9Home PD, Gubb J. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes(RECORD): a long-term cardiovascular outcome study. Diabetes, 2002,51 (Suppl 2): A487. 被引量：1
10Tadayyon M, Swith SA. Insulin sensitization in the treatment of type 2 diabetes. Expert Opin Invest Drugs,2003,12:307-324. 被引量：1
6Seale FG 4th,Robinson RD,Neal GS.Association of metformin and pregnancy in the polycystic ovary syndrome.A report of three cases[J].J Reprod Med,2000,45(6):507-510. 被引量：1
7Spranger J,Mohlig M,Wegewitz U,et al.Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome[J].Obstet Gynecol Surv,2005,60(4):237-239. 被引量：1
8Kilicdag EB,Bagis T,Zeyneloglu HB,et al.Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone:a randomized study[J].Hum Reprod,2005,20(4):894-899. 被引量：1
